February 17, 2020
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
CANDLE
Issue: February 2020
Noninferiority of canagliflozin (Invokana, Janssen) vs. the sulfonylurea glimepiride in HF outcomes.
